8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Apr 23, 2026·SEC
BioMarin Pharmaceutical Inc.(BMRN)Earnings, Financials & Key Ratios
BMRN•NASDAQ
30.4× P/E·Price updated Jun 19, 2026
AboutBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.Show more
- Revenue$3.22B+12.9%
- EBITDA$613M+5.6%
- Net Income$349M-18.3%
- EPS (Diluted)1.80-18.6%
- Gross Margin77.13%-3.2%
- EBITDA Margin19.03%-6.5%
- Operating Margin16.56%-2.4%
- Net Margin10.83%-27.6%
- ROE5.94%-26.2%
BMRN Key Insights
BioMarin Pharmaceutical Inc. (BMRN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 22.5% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 11.6%
✗Weaknesses
- ✗Profits declining 16.4% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BMRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BMRN Price & Volume
BioMarin Pharmaceutical Inc. (BMRN) stock price & volume — 10-year historical chart
Loading chart...
BMRN Growth Metrics
BioMarin Pharmaceutical Inc. (BMRN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years13.73%
5 Years11.6%
3 Years15.4%
TTM9.9%
Profit CAGR
10 Years-
5 Years-16.39%
3 Years35.08%
TTM-48.7%
EPS CAGR
10 Years-
5 Years-16.86%
3 Years33.89%
TTM-48.33%
Return on Capital
10 Years-0.99%
5 Years4.14%
3 Years6.45%
Last Year8.07%
BMRN Recent Earnings
BioMarin Pharmaceutical Inc. (BMRN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.76-19.1%
$0.94
Rev
$766M+1.8%
$753M
Q1 2026
Feb 23, 2026Metric
Actual
Est
EPS
$0.24-241.7%
$0.17
Rev
$875M+4.9%
$834M
Q4 2025
Oct 27, 2025Metric
Actual
Est
EPS
$0.12+180.0%
$0.15
Rev
$776M-5.7%
$823M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$1.44+67.2%
$0.86
Rev
$825M+8.3%
$762M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.76vs $0.94-19.1% | $766Mvs $753M+1.8% |
| Q1 2026 | Feb 23, 2026 | $0.24vs $0.17-241.7% | $875Mvs $834M+4.9% |
| Q4 2025 | Oct 27, 2025 | $0.12vs $0.15+180.0% | $776Mvs $823M-5.7% |
| Q3 2025 | Aug 4, 2025 | $1.44vs $0.86+67.2% | $825Mvs $762M+8.3% |
Based on last 12 quarters of dataView full earnings history →
BMRN Peer Comparison
BioMarin Pharmaceutical Inc. (BMRN) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% |
Compare BMRN vs Peers
BioMarin Pharmaceutical Inc. (BMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BMRN Income Statement
BioMarin Pharmaceutical Inc. (BMRN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.31B | 1.49B | 1.7B | 1.86B | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B | 3.24B |
Revenue Growth % | 17.62% | 13.52% | 14.27% | 9.18% | -0.76% | 13.53% | 15.42% | 17.97% | 12.87% | 9.9% |
Cost of Goods Sold | 241.79M | 315.26M | 359.47M | 524.27M | 470.51M | 503.02M | 532.06M | 580.24M | 736.83M | 780.27M |
COGS % of Revenue | 18.41% | 21.14% | 21.09% | 28.18% | 25.48% | 24% | 21.99% | 20.33% | 22.87% | - |
Gross Profit | 1.07B▲ 0% | 1.18B▲ 9.7% | 1.34B▲ 14.3% | 1.34B▼ 0.6% | 1.38B▲ 3.0% | 1.59B▲ 15.8% | 1.89B▲ 18.5% | 2.27B▲ 20.5% | 2.48B▲ 9.3% | 2.46B▲ 0% |
Gross Margin % | 81.59% | 78.86% | 78.91% | 71.82% | 74.52% | 76% | 78.01% | 79.67% | 77.13% | 75.93% |
Gross Profit Growth % | 18.15% | 9.72% | 14.34% | -0.62% | 2.96% | 15.79% | 18.46% | 20.48% | 9.27% | - |
Operating Expenses | 1.09B | 1.3B | 1.45B | 1.38B | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B | 2.02B |
OpEx % of Revenue | 82.71% | 87.14% | 84.8% | 74.16% | 78.98% | 68.32% | 70.33% | 62.7% | 60.56% | - |
Selling, General & Admin | 554.34M | 604.4M | 680.9M | 737.7M | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B | 1.56B |
SG&A % of Revenue | 42.2% | 40.53% | 39.96% | 39.65% | 41.13% | 39.27% | 36.89% | 35.35% | 39.64% | - |
Research & Development | 610.75M | 696.33M | 715.01M | 628.12M | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M | 942M |
R&D % of Revenue | 46.49% | 46.69% | 41.96% | 33.76% | 34.06% | 30.99% | 30.87% | 26.18% | 28.62% | - |
Other Operating Expenses | -78.53M | -1.21M | 49.13M | 13.81M | 69.91M | -40.76M | 62.22M | 33.28M | -248M | 2M |
Operating Income | -14.7M▲ 0% | -123.52M▼ 740.3% | -100.46M▲ 18.7% | -43.44M▲ 56.8% | -82.34M▼ 89.6% | 160.97M▲ 295.5% | 185.77M▲ 15.4% | 484.21M▲ 160.6% | 533.48M▲ 10.2% | 447.22M▲ 0% |
Operating Margin % | -1.12% | -8.28% | -5.9% | -2.33% | -4.46% | 7.68% | 7.68% | 16.97% | 16.56% | 13.79% |
Operating Income Growth % | 98.17% | -740.3% | 18.67% | 56.76% | -89.55% | 295.5% | 15.41% | 160.65% | 10.17% | - |
EBITDA | 73.16M | -27.85M | 4.84M | 61.73M | 25.7M | 262.94M | 290.16M | 580.64M | 613.03M | 521.12M |
EBITDA Margin % | 5.57% | -1.87% | 0.28% | 3.32% | 1.39% | 12.54% | 11.99% | 20.35% | 19.03% | 16.07% |
EBITDA Growth % | 110.36% | -138.07% | 117.39% | 1174.66% | -58.37% | 923.2% | 10.35% | 100.11% | 5.58% | -26.68% |
D&A (Non-Cash Add-back) | 87.86M | 95.67M | 105.3M | 105.17M | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M | 73.9M |
EBIT | 3.11M | -99.04M | -73.38M | -21.52M | -60.61M | 163.39M | 202.39M | 554.1M | 493.38M | 390.07M |
Net Interest Income | -27.85M | -20.83M | -712K | -12.7M | -4.86M | 2.06M | 41M | 62.15M | 64M | 55.46M |
Interest Income | 14.85M | 22.83M | 22.75M | 16.61M | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M | 78.45M |
Interest Expense | 42.71M | 43.66M | 23.46M | 29.31M | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M | 22.99M |
Other Income/Expense | -21.18M | -19.18M | 5.65M | -5.56M | 6.99M | -11.4M | 2.79M | 57.55M | -51M | -53.63M |
Pretax Income | -35.88M▲ 0% | -142.71M▼ 297.8% | -94.81M▲ 33.6% | -49M▲ 48.3% | -75.35M▼ 53.8% | 149.58M▲ 298.5% | 188.56M▲ 26.1% | 541.76M▲ 187.3% | 482.48M▼ 10.9% | 385.59M▲ 0% |
Pretax Margin % | -2.73% | -9.57% | -5.56% | -2.63% | -4.08% | 7.14% | 7.79% | 18.98% | 14.98% | 11.89% |
Income Tax | 81.17M | -65.49M | -70.96M | -903.03M | -11.27M | 8.02M | 20.92M | 114.9M | 133.58M | 116.85M |
Effective Tax Rate % | -226.25% | 45.89% | 74.85% | 1843.02% | 14.96% | 5.36% | 11.09% | 21.21% | 27.69% | 30.3% |
Net Income | -117.04M▲ 0% | -77.21M▲ 34.0% | -23.85M▲ 69.1% | 854.03M▲ 3681.1% | -64.08M▼ 107.5% | 141.56M▲ 320.9% | 167.65M▲ 18.4% | 426.86M▲ 154.6% | 348.9M▼ 18.3% | 268.74M▲ 0% |
Net Margin % | -8.91% | -5.18% | -1.4% | 45.9% | -3.47% | 6.75% | 6.93% | 14.96% | 10.83% | 8.29% |
Net Income Growth % | 81.43% | 34.03% | 69.11% | 3681.13% | -107.5% | 320.91% | 18.43% | 154.62% | -18.26% | -48.7% |
Net Income (Continuing) | -117.04M | -77.21M | -23.85M | 854.03M | -64.08M | 141.56M | 167.65M | 426.86M | 348.9M | 268.74M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.67▲ 0% | -0.44▲ 34.3% | -0.13▲ 70.5% | 4.53▲ 3584.6% | -0.35▼ 107.7% | 0.75▲ 314.3% | 0.88▲ 17.3% | 2.21▲ 151.1% | 1.80▼ 18.6% | 1.36▲ 0% |
EPS Growth % | 82.32% | 34.33% | 70.45% | 3584.62% | -107.73% | 314.29% | 17.33% | 151.14% | -18.55% | -48.33% |
EPS (Basic) | -0.67 | -0.44 | -0.13 | 4.75 | -0.35 | 0.76 | 0.89 | 2.25 | 1.82 | - |
Diluted Shares Outstanding | 174.43M | 177.27M | 179.04M | 191.68M | 182.85M | 188.96M | 191.59M | 196.71M | 197.39M | 197.67M |
Basic Shares Outstanding | 174.43M | 177.06M | 179.04M | 180.8M | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M | 192.5M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BMRN Balance Sheet
BioMarin Pharmaceutical Inc. (BMRN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.21B | 2.06B | 1.94B | 2.34B | 2.27B | 2.75B | 2.96B | 3.23B | 3.95B | 4.61B |
Cash & Short-Term Investments | 1.4B | 1.08B | 753.81M | 1.07B | 1.01B | 1.29B | 1.07B | 1.14B | 1.56B | 2.22B |
Cash Only | 598.03M | 493.98M | 437.45M | 649.16M | 587.28M | 724.53M | 755.13M | 942.84M | 1.31B | 2.22B |
Short-Term Investments | 797.94M | 590.33M | 316.36M | 416.23M | 426.6M | 567.01M | 318.68M | 194.86M | 248.93M | 0 |
Accounts Receivable | 261.37M | 342.63M | 377.4M | 448.35M | 373.4M | 461.32M | 633.7M | 660.53M | 908.21M | 903.91M |
Days Sales Outstanding | 72.62 | 83.86 | 80.84 | 87.96 | 73.82 | 80.33 | 95.61 | 84.48 | 102.91 | 97.33 |
Inventory | 475.77M | 530.87M | 680.27M | 698.55M | 776.67M | 894.08M | 1.11B | 1.23B | 1.3B | 1.27B |
Days Inventory Outstanding | 718.23 | 614.62 | 690.75 | 486.33 | 602.5 | 648.76 | 759.54 | 775.41 | 643.42 | 619.17 |
Other Current Assets | 74.04M | 98.4M | 130.66M | 129.93M | 110.44M | 104.52M | 141.39M | 201.53M | 185.78M | 205.5M |
Total Non-Current Assets | 2.43B | 2.37B | 2.75B | 3.51B | 3.73B | 3.62B | 3.89B | 3.76B | 3.64B | 3.99B |
Property, Plant & Equipment | 896.7M | 948.68M | 1.01B | 1.03B | 1.04B | 1.07B | 1.07B | 1.04B | 952.51M | 958.07M |
Fixed Asset Turnover | 1.46x | 1.57x | 1.69x | 1.80x | 1.78x | 1.95x | 2.27x | 2.74x | 3.38x | 3.26x |
Goodwill | 197.04M | 197.04M | 197.04M | 196.2M | 196.2M | 196.2M | 196.2M | 196.2M | 196.2M | 196.2M |
Intangible Assets | 517.51M | 491.81M | 456.58M | 417.27M | 388.65M | 338.57M | 294.7M | 255.28M | 213.84M | 204.66M |
Long-Term Investments | 385.79M | 235.86M | 411.98M | 285.47M | 507.79M | 333.83M | 611.13M | 521.24M | 498.21M | 2.37B |
Other Non-Current Assets | 29.85M | 36.57M | 122.01M | 142.24M | 152.12M | 176.24M | 171.54M | 251.39M | 277.05M | 276.42M |
Total Assets | 4.63B▲ 0% | 4.43B▼ 4.4% | 4.69B▲ 5.9% | 5.85B▲ 24.7% | 6B▲ 2.7% | 6.38B▲ 6.2% | 6.84B▲ 7.3% | 6.99B▲ 2.2% | 7.59B▲ 8.7% | 8.59B▲ 0% |
Asset Turnover | 0.28x | 0.34x | 0.36x | 0.32x | 0.31x | 0.33x | 0.35x | 0.41x | 0.42x | 0.41x |
Asset Growth % | 15.15% | -4.45% | 5.94% | 24.69% | 2.68% | 6.17% | 7.32% | 2.15% | 8.66% | 45.52% |
Total Current Liabilities | 816.52M | 523.24M | 932.5M | 492.55M | 546.5M | 588.88M | 1.18B | 606.99M | 759.03M | 793.15M |
Accounts Payable | 166.62M | 207.62M | 240.98M | 191.43M | 199.68M | 231.24M | 315.51M | 235.4M | 312.77M | 793.15M |
Days Payables Outstanding | 251.52 | 240.37 | 244.69 | 133.27 | 154.9 | 167.79 | 216.44 | 148.08 | 154.93 | 211.25 |
Short-Term Debt | 360.95M | 0 | 361.88M | 0 | 0 | 0 | 493.88M | 23.07M | 8.69M | 0 |
Deferred Revenue (Current) | 0 | 1.47M | 13.04M | 152K | 6.96M | 711K | 4.62M | 1.37M | 0 | 0 |
Other Current Liabilities | 208.89M | 240.07M | 202.91M | 182.82M | 258.94M | 236.1M | 234.92M | 132.06M | 210.72M | 0 |
Current Ratio | 2.70x | 3.93x | 2.08x | 4.76x | 4.16x | 4.67x | 2.51x | 5.33x | 5.21x | 5.81x |
Quick Ratio | 2.12x | 2.92x | 1.35x | 3.34x | 2.74x | 3.15x | 1.57x | 3.29x | 3.50x | 4.20x |
Cash Conversion Cycle | 539.33 | 458.11 | 526.9 | 441.02 | 521.42 | 561.3 | 638.71 | 711.8 | 591.4 | 505.24 |
Total Non-Current Liabilities | 1.01B | 935.95M | 635.15M | 1.25B | 1.19B | 1.18B | 713.03M | 723.96M | 747.99M | 1.59B |
Long-Term Debt | 813.52M | 830.42M | 486.24M | 1.08B | 1.08B | 1.08B | 593.1M | 595.14M | 597.18M | 1.43B |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31.26M | 37.01M | 37.01M |
Deferred Tax Liabilities | 44.32M | 62.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 194.42M | 105.53M | 148.92M | 174.32M | 113.53M | 100.02M | 119.94M | 97.57M | 113.8M | 155.47M |
Total Liabilities | 1.82B | 1.46B | 1.57B | 1.74B | 1.74B | 1.77B | 1.89B | 1.33B | 1.51B | 2.38B |
Total Debt | 1.17B | 830.42M | 858.82M | 1.09B | 1.09B | 1.09B | 1.1B | 649.47M | 642.87M | 1.43B |
Net Debt | 576.44M | 336.44M | 421.37M | 437.74M | 502.26M | 368.86M | 340.62M | -293.38M | -668.81M | -792.15M |
Debt / Equity | 0.42x | 0.28x | 0.28x | 0.26x | 0.26x | 0.24x | 0.22x | 0.11x | 0.11x | 0.23x |
Debt / EBITDA | 16.05x | - | 177.33x | 17.61x | 42.40x | 4.16x | 3.78x | 1.12x | 1.05x | 2.74x |
Net Debt / EBITDA | 7.88x | - | 87.01x | 7.09x | 19.54x | 1.40x | 1.17x | -0.51x | -1.09x | -1.52x |
Interest Coverage | 0.07x | -2.27x | -3.13x | -0.73x | -3.95x | 10.23x | 11.68x | 43.75x | 45.27x | 16.96x |
Total Equity | 2.81B▲ 0% | 2.97B▲ 5.7% | 3.12B▲ 5.2% | 4.11B▲ 31.5% | 4.27B▲ 3.9% | 4.6B▲ 7.9% | 4.95B▲ 7.6% | 5.66B▲ 14.3% | 6.09B▲ 7.6% | 6.21B▲ 0% |
Equity Growth % | 1.53% | 5.67% | 5.2% | 31.5% | 3.89% | 7.91% | 7.57% | 14.27% | 7.58% | 40.71% |
Book Value per Share | 16.10 | 16.74 | 17.44 | 21.42 | 23.33 | 24.36 | 25.84 | 28.76 | 30.84 | 31.43 |
Total Shareholders' Equity | 2.81B | 2.97B | 3.12B | 4.11B | 4.27B | 4.6B | 4.95B | 5.66B | 6.09B | 6.21B |
Common Stock | 176K | 178K | 180K | 182K | 184K | 186K | 189K | 191K | 192K | -10.26M |
Retained Earnings | -1.64B | -1.69B | -1.72B | -861.61M | -930.76M | -789.2M | -621.55M | -194.69M | 154.21M | 259.73M |
Treasury Stock | -14.22M | -13.3M | -9.96M | -9.84M | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -22.96M | 5.27M | 20.16M | -16.14M | 14.43M | -3.87M | -28.79M | 61.65M | -23.98M | -4.24M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BMRN Cash Flow Statement
BioMarin Pharmaceutical Inc. (BMRN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.76M | 20.21M | 48.26M | 85.36M | 304.54M | 175.9M | 159.26M | 572.84M | 827.99M | 874.25M |
Operating CF Margin % | -0.67% | 1.36% | 2.83% | 4.59% | 16.49% | 8.39% | 6.58% | 20.07% | 25.7% | - |
Operating CF Growth % | 96.16% | 330.76% | 138.83% | 76.88% | 256.75% | -42.24% | -9.46% | 259.69% | 44.54% | 102.67% |
Net Income | -117.04M | -77.21M | -23.85M | 859.1M | -64.08M | 141.56M | 167.65M | 426.86M | 348.9M | 268.74M |
Depreciation & Amortization | 87.86M | 95.67M | 105.3M | 105.17M | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M | 73.9M |
Stock-Based Compensation | 140.26M | 148.82M | 159.87M | 189.71M | 197.26M | 196.31M | 207.1M | 201.57M | 181.41M | 187.17M |
Deferred Taxes | 44.46M | -68.38M | -82.76M | -888.91M | -15.61M | -52.09M | -44.98M | 56.1M | 48.74M | 29.53M |
Other Non-Cash Items | -70.34M | -29.27M | -9.2M | 44.71M | 12.89M | -115.47M | 61.65M | 8.29M | 278.07M | -77.31M |
Working Capital Changes | -93.96M | -49.42M | -101.09M | -224.42M | 66.03M | -96.38M | -336.54M | -216.4M | -108.68M | 20.85M |
Change in Receivables | -25.26M | -54.27M | -37.85M | -59.03M | 65.57M | -82.03M | -190.44M | -57.91M | -228.05M | -177.62M |
Change in Inventory | -96.89M | -23.75M | -107.55M | -61.15M | -35.06M | -68.26M | -157.06M | -63.53M | 119.21M | 188.03M |
Change in Payables | 24.83M | 20.62M | 77.09M | -68.71M | 15.69M | 59.02M | 68.85M | -32.24M | 66.14M | 71.89M |
Cash from Investing | -305.46M | 264.35M | -31.03M | -53.62M | -366.31M | -20.03M | -111.24M | 136.49M | -414.24M | 339.52M |
Capital Expenditures | -199.22M | -144.62M | -163.41M | -137.52M | -95.58M | -131.54M | -107.61M | -85.42M | -103.04M | -112.5M |
CapEx % of Revenue | 15.17% | 9.7% | 9.59% | 7.39% | 5.18% | 6.28% | 4.45% | 2.99% | 3.2% | 3.47% |
Acquisitions | 125M | 50M | 0 | -23.21M | 0 | 0 | 0 | 0 | -285.19M | -285.19M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.75M | -10K | 24.19M | 89.64M | -24.64M | 103.33M | 0 | -853K | -7.94M | 2.33M |
Cash from Financing | 507.14M | -388.01M | -74.67M | 181.12M | -48K | -18.65M | -18.73M | -526.45M | -42.39M | 809.55M |
Debt Issued (Net) | 481.69M | -374.95M | -5.09M | 203.84M | -3.04M | -2.6M | -2.29M | -494.99M | 0 | 841.35M |
Equity Issued (Net) | 0 | 0 | 31.61M | -50M | 0 | 69.33M | 69.35M | 0 | 0 | -23.36M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -33.51M | -35.92M | 0 | -50M | 0 | 0 | 0 | 0 | 0 | -38.78M |
Other Financing | 25.46M | -13.05M | -101.2M | 27.27M | 2.99M | -85.38M | -85.79M | -31.46M | -42.39M | -8.44M |
Net Change in Cash | 189.7M▲ 0% | -104.05M▼ 154.8% | -56.54M▲ 45.7% | 211.71M▲ 474.5% | -61.88M▼ 129.2% | 137.25M▲ 321.8% | 30.6M▼ 77.7% | 187.72M▲ 513.5% | 368.84M▲ 96.5% | 2.02B▲ 0% |
Free Cash Flow | -207.98M▲ 0% | -124.41M▲ 40.2% | -96.76M▲ 22.2% | -52.15M▲ 46.1% | 185.31M▲ 455.3% | 54.94M▼ 70.4% | 62.57M▲ 13.9% | 475.42M▲ 659.9% | 724.96M▲ 52.5% | 767.06M▲ 0% |
FCF Margin % | -15.83% | -8.34% | -5.68% | -2.8% | 10.04% | 2.62% | 2.59% | 16.66% | 22.51% | 23.66% |
FCF Growth % | 44.72% | 40.18% | 22.22% | 46.1% | 455.31% | -70.35% | 13.88% | 659.85% | 52.49% | 23.68% |
FCF per Share | -1.19 | -0.70 | -0.54 | -0.27 | 1.01 | 0.29 | 0.33 | 2.42 | 3.67 | 3.88 |
FCF Conversion (FCF/Net Income) | 0.07x | -0.26x | -2.02x | 0.10x | -4.75x | 1.24x | 0.95x | 1.34x | 2.37x | 2.85x |
Interest Paid | 8.54M | 11.62M | 0 | 12.18M | 10.39M | 0 | 0 | 10.36M | 0 | 3.57M |
Taxes Paid | 23.89M | 16.68M | 0 | 8.98M | 18.15M | 0 | 0 | 57.27M | 0 | 59.82M |
BMRN Key Ratios
BioMarin Pharmaceutical Inc. (BMRN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -4.2% | -2.67% | -0.78% | 23.63% | -1.53% | 3.19% | 3.51% | 8.05% | 5.94% | 4.41% |
Return on Invested Capital (ROIC) | -0.34% | -2.77% | -2.2% | -0.81% | -1.33% | 2.48% | 2.71% | 6.82% | 7.42% | 6.19% |
Gross Margin | 81.59% | 78.86% | 78.91% | 71.82% | 74.52% | 76% | 78.01% | 79.67% | 77.13% | 75.93% |
Net Margin | -8.91% | -5.18% | -1.4% | 45.9% | -3.47% | 6.75% | 6.93% | 14.96% | 10.83% | 8.29% |
Debt / Equity | 0.42x | 0.28x | 0.28x | 0.26x | 0.26x | 0.24x | 0.22x | 0.11x | 0.11x | 0.23x |
Interest Coverage | 0.07x | -2.27x | -3.13x | -0.73x | -3.95x | 10.23x | 11.68x | 43.75x | 45.27x | 16.96x |
FCF Conversion | 0.07x | -0.26x | -2.02x | 0.10x | -4.75x | 1.24x | 0.95x | 1.34x | 2.37x | 2.85x |
Revenue Growth | 17.62% | 13.52% | 14.27% | 9.18% | -0.76% | 13.53% | 15.42% | 17.97% | 12.87% | 9.9% |
Related:BMRN Dividend History·BMRN Revenue History·BMRN Price History·BMRN P/E History·BMRN Financial Ratios·BMRN Institutional Holders
BMRN SEC Filings & Documents
BioMarin Pharmaceutical Inc. (BMRN) SEC filings — annual & quarterly reports (10-K, 10-Q)
BMRN Frequently Asked Questions
BioMarin Pharmaceutical Inc. (BMRN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioMarin Pharmaceutical Inc. (BMRN) reported $3.24B in revenue for fiscal year 2025. This represents a 270093% increase from $1.2M in 1998.
BioMarin Pharmaceutical Inc. (BMRN) grew revenue by 12.9% over the past year. This is steady growth.
Yes, BioMarin Pharmaceutical Inc. (BMRN) is profitable, generating $268.7M in net income for fiscal year 2025 (10.8% net margin).
Dividend & Returns
BioMarin Pharmaceutical Inc. (BMRN) has a return on equity (ROE) of 5.9%. This is below average, suggesting room for improvement.
BioMarin Pharmaceutical Inc. (BMRN) generated $767.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.